134 related articles for article (PubMed ID: 10522872)
1. Incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France.
Huillard d'Aignaux J; Costagliola D; Maccario J; Billette de Villemeur T; Brandel JP; Deslys JP; Hauw JJ; Chaussain JL; Agid Y; Dormont D; Alpérovitch A
Neurology; 1999 Oct; 53(6):1197-201. PubMed ID: 10522872
[TBL] [Abstract][Full Text] [Related]
2. Creutzfeldt-Jakob disease risk in Slovak recipients of human pituitary growth hormone.
Mitrova E; Belay G
Bratisl Lek Listy; 1999 Apr; 100(4):187-91. PubMed ID: 10914140
[TBL] [Abstract][Full Text] [Related]
3. Prion strains associated with iatrogenic CJD in French and UK human growth hormone recipients.
Douet JY; Huor A; Cassard H; Lugan S; Aron N; Mesic C; Vilette D; Barrio T; Streichenberger N; Perret-Liaudet A; Delisle MB; Péran P; Deslys JP; Comoy E; Vilotte JL; Goudarzi K; Béringue V; Barria MA; Ritchie DL; Ironside JW; Andréoletti O
Acta Neuropathol Commun; 2021 Aug; 9(1):145. PubMed ID: 34454616
[TBL] [Abstract][Full Text] [Related]
4. A statistical model to identify the contaminated lots implicated in iatrogenic transmission of Creutzfeldt-Jakob disease among French human growth hormone recipients.
Huillard d'Aignaux J; Alpérovitch A; Maccario J
Am J Epidemiol; 1998 Mar; 147(6):597-604. PubMed ID: 9521187
[TBL] [Abstract][Full Text] [Related]
5. Lower risk of Creutzfeldt-Jakob disease in pituitary growth hormone recipients initiating treatment after 1977.
Abrams JY; Schonberger LB; Belay ED; Maddox RA; Leschek EW; Mills JL; Wysowski DK; Fradkin JE
J Clin Endocrinol Metab; 2011 Oct; 96(10):E1666-9. PubMed ID: 21816775
[TBL] [Abstract][Full Text] [Related]
6. Creutzfeldt-Jakob disease in pituitary growth hormone recipients in the United States.
Fradkin JE; Schonberger LB; Mills JL; Gunn WJ; Piper JM; Wysowski DK; Thomson R; Durako S; Brown P
JAMA; 1991 Feb; 265(7):880-4. PubMed ID: 1992185
[TBL] [Abstract][Full Text] [Related]
7. Creutzfeldt-Jakob disease 38 years after diagnostic use of human growth hormone.
Croes EA; Roks G; Jansen GH; Nijssen PC; van Duijn CM
J Neurol Neurosurg Psychiatry; 2002 Jun; 72(6):792-3. PubMed ID: 12023427
[TBL] [Abstract][Full Text] [Related]
8. Amyloid-β accumulation in the CNS in human growth hormone recipients in the UK.
Ritchie DL; Adlard P; Peden AH; Lowrie S; Le Grice M; Burns K; Jackson RJ; Yull H; Keogh MJ; Wei W; Chinnery PF; Head MW; Ironside JW
Acta Neuropathol; 2017 Aug; 134(2):221-240. PubMed ID: 28349199
[TBL] [Abstract][Full Text] [Related]
9. The French surveillance network of Creutzfeldt-Jakob disease. Epidemiological data in France and worldwide.
Brandel JP; Peckeu L; Haïk S
Transfus Clin Biol; 2013 Sep; 20(4):395-7. PubMed ID: 23587616
[TBL] [Abstract][Full Text] [Related]
10. Distribution of codon 129 genotype in human growth hormone-treated CJD patients in France and the UK.
Brandel JP; Preece M; Brown P; Croes E; Laplanche JL; Agid Y; Will R; Alpérovitch A
Lancet; 2003 Jul; 362(9378):128-30. PubMed ID: 12867116
[TBL] [Abstract][Full Text] [Related]
11. Neuropathology of iatrogenic Creutzfeldt-Jakob disease and immunoassay of French cadaver-sourced growth hormone batches suggest possible transmission of tauopathy and long incubation periods for the transmission of Abeta pathology.
Duyckaerts C; Sazdovitch V; Ando K; Seilhean D; Privat N; Yilmaz Z; Peckeu L; Amar E; Comoy E; Maceski A; Lehmann S; Brion JP; Brandel JP; Haïk S
Acta Neuropathol; 2018 Feb; 135(2):201-212. PubMed ID: 29209767
[TBL] [Abstract][Full Text] [Related]
12. Iatrogenic Creutzfeldt-Jakob disease in Australia: time to amend infection control measures for pituitary hormone recipients?
Boyd A; Klug GM; Schonberger LB; McGlade A; Brandel JP; Masters CL; Collins SJ
Med J Aust; 2010 Sep; 193(6):366-9. PubMed ID: 20854243
[TBL] [Abstract][Full Text] [Related]
13. Creutzfeldt-Jakob disease in United Kingdom patients treated with human pituitary growth hormone.
Swerdlow AJ; Higgins CD; Adlard P; Jones ME; Preece MA
Neurology; 2003 Sep; 61(6):783-91. PubMed ID: 14504321
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility to Creutzfeldt-Jakob disease after human growth hormone treatment in France.
Peckeu L; Brandel JP; Welaratne A; Costagliola D; Haïk S
Neurology; 2018 Aug; 91(8):e724-e731. PubMed ID: 30045957
[TBL] [Abstract][Full Text] [Related]
15. Iatrogenic Creutzfeldt-Jakob disease at the millennium.
Brown P; Preece M; Brandel JP; Sato T; McShane L; Zerr I; Fletcher A; Will RG; Pocchiari M; Cashman NR; d'Aignaux JH; Cervenáková L; Fradkin J; Schonberger LB; Collins SJ
Neurology; 2000 Oct; 55(8):1075-81. PubMed ID: 11071481
[TBL] [Abstract][Full Text] [Related]
16. [Incidence of Creutzfeldt-Jakob disease in France, 1992-1995].
Ruffié A; Delasnerie-Lauprêtre N; Brandel JP; Jaussent I; Dormont D; Laplanche JL; Hauw JJ; Richardson S; Alpérovitch A
Rev Epidemiol Sante Publique; 1997 Dec; 45(6):448-53. PubMed ID: 9496575
[TBL] [Abstract][Full Text] [Related]
17. Similar genetic susceptibility in iatrogenic and sporadic Creutzfeldt-Jakob disease.
Deslys JP; Marcé D; Dormont D
J Gen Virol; 1994 Jan; 75 ( Pt 1)():23-7. PubMed ID: 8113733
[TBL] [Abstract][Full Text] [Related]
18. [Epidemiological surveillance of Creutzfeldt-Jakob in France].
Brandel JP; Salomon D; Capek I; Vaillant V; Alpérovitch A
Rev Neurol (Paris); 2009; 165(8-9):684-93. PubMed ID: 19467685
[TBL] [Abstract][Full Text] [Related]
19. A nationwide cohort study on Creutzfeldt-Jakob disease among human growth hormone recipients.
Wientjens DP; Rikken B; Wit JM; Hofman A; Stricker BH
Neuroepidemiology; 2000; 19(4):201-5. PubMed ID: 10859499
[TBL] [Abstract][Full Text] [Related]
20. Familial Creutzfeldt-Jakob disease in France: epidemiological implications.
Baron H; Cathala F; Brown P; Chatelain J; Gajdusek DC
Eur J Epidemiol; 1986 Dec; 2(4):252-64. PubMed ID: 3542553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
